Meletios A. Dimopoulos, Meral Beksac, Sosana Delimpasi, Vladimir I. Vorobyev, Hang Quach, Ivan Špička, Jakub Radocha, Pawel Robak, Kihyun Kim, Michele Cavo, Syed Farhan Zafar, Ainslee Moore, Kristin Morris, Margaret Polinkovsky, Kelly Brock, Joanna Grams, Elisabet Manasanch, María-Victoria Mateos, Suzanne Trudel. "Durable clinical benefit with B-cell maturation antigen (BCMA)–directed therapy, belantamab mafodotin plus pomalidomide and dexamethasone (BPd) in relapsed/refractory multiple myeloma (RRMM): DREAMM-8 long-term responder (LTR) analysis.." Journal of Clinical Oncology, 2026. doi:10.1200/jco.2026.44.16_suppl.7565